Literature DB >> 29759624

Long Detection Programming in Single-Chamber Defibrillators Reduces Unnecessary Therapies and Mortality: The ADVANCE III Trial.

Maurizio Gasparini1, Maurizio G Lunati2, Alessandro Proclemer3, Angel Arenal4, Axel Kloppe5, Josè B Martínez Ferrer6, Ahmad S Hersi7, Marcin Gulaj8, Maurits C E Wijffels9, Elisabetta Santi10, Laura Manotta11, Niraj Varma12.   

Abstract

OBJECTIVES: This study sought to evaluate the effects of programming a long detection in single-chamber (VVI) implantable cardioverter-defibrillators (ICDs) in the multicenter prospective ADVANCE III (Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III) trial.
BACKGROUND: Programming strategies may reduce unnecessary ICD shocks and their adverse effects but to date have been described only for dual-chamber ICDs.
METHODS: A total of 545 subjects (85% male; atrial fibrillation 25%, left ventricular ejection fraction 31%, ischemic etiology 68%, secondary prevention indications 32%) receiving a VVI ICD were randomized to long detection (30 of 40 intervals) or standard programming (18 of 24 intervals) based on device type, atrial fibrillation history, and indication. In both arms, antitachycardia pacing (ATP) therapy during charging was programmed for episodes with cycle length 320 to 200 ms and shock only for cycle length <200 ms. Wavelet and stability functions enabled. Therapies delivered were compared using a negative binomial regression model.
RESULTS: A total of 267 patients were randomized to long detection and 278 to the control group. Median follow-up was 12 months. One hundred twelve therapies (shocks and ATP) occurred in the long detection arm versus 257 in the control arm, for a 48% reduction with 30 of 40 intervals (95% confidence interval [CI]: 0.36 to 0.76; p = 0.002). In the long detection arm, overall shocks were reduced by 40% compared to the control arm (48 vs. 24; 95% CI: 0.38 to 0.94; p = 0.026) and appropriate shocks by 51% (34 vs. 74; 95% CI: 0.26 to 0.94; p = 0.033). Syncopal events did not differ between arms, but survival improved in the long detection arm.
CONCLUSIONS: Among patients implanted with a VVI ICD, programming with the long detection interval significantly reduced appropriate therapies, shocks, and all-cause mortality. (Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III [ADVANCEIII]; NCT00617175).
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  implantable cardioverter-defibrillator; inappropriate therapies; mortality; shocks

Mesh:

Year:  2017        PMID: 29759624     DOI: 10.1016/j.jacep.2017.05.001

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  4 in total

1.  Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study.

Authors:  Pier D Lambiase; Dominic A Theuns; Francis Murgatroyd; Craig Barr; Lars Eckardt; Petr Neuzil; Marcoen Scholten; Margaret Hood; Jȕrgen Kuschyk; Amy J Brisben; Nathan Carter; Timothy M Stivland; Reinoud Knops; Lucas V A Boersma
Journal:  Eur Heart J       Date:  2022-06-01       Impact factor: 35.855

2.  How Well Do Results From Randomized Clinical Trials and/or Recommendations for Implantable Cardioverter-Defibrillator Programming Diffuse Into Clinical Practice?Translation Assessed in a National Cohort of Patients With Implantable Cardioverter-Defibrillators ( ALTITUDE ).

Authors:  Niraj Varma; Paul Jones; Nicholas Wold; Edmond Cronin; Kenneth Stein
Journal:  J Am Heart Assoc       Date:  2019-02-05       Impact factor: 5.501

3.  The wearable cardioverter-defibrillator-Improving comfort and reaching towards noise immunity.

Authors:  Niraj Varma
Journal:  J Cardiovasc Electrophysiol       Date:  2022-02-27       Impact factor: 2.942

4.  One size fits all, or do we have to rethink optimal programming in implantable cardioverter-defibrillators implanted for secondary prevention?

Authors:  Ivan Cakulev; Judith A Mackall
Journal:  Heart Rhythm O2       Date:  2020-05-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.